Biopharma stocks: 3 Small-caps that have bottomed out in November

By Jorge Aura

All investors know the risks of biotechnology companies. The strong volatility of these companies makes their prices fluctuate in excess. This sector has the peculiarity that offers a high risk but with a possible high gain. Identify pharmaceutical companies that have bottomed out or that are undervalued can be a good investment strategy for medium-term and short-term. In the following table will be able to see the readers, 3 companies which have greatly reduced their quoted prices since on January 3, 2012.

Company	January 3, 2012	52-wk low on November 2012	%
Dynavax Technologies Corporation	$3.28	$2.22	-32.32%
Horizon Pharma	$4.20	$2.03	-51
Somaxon Pharmaceuticals	$3.68	$1.29	-64.95%

As you have seen in the upper table these companies have been hit hard during November, 2012. To determine if these companies are undervalued I have made a fundamental analysis of each company.

Dynavax Technologies Corporation (NASDAQ: DVAX) is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences.

Dynavax's lead product candidate is Heplisav. This product candidate is in Phase III to treat adult hepatitis B. Heplisav is an experimental vaccine. On November 15, 2012 Dynavax announced that FDA Vaccines and Related Biological Products Advisory Committee voted thirteen to one that Heplisav data adequately demonstrated immunogenicity. But the same Committee voted eight to five with one abstention that there was insufficient data to adequately support the safety of Heplisav.

Dynavax has a market cap of $489.66 million. Its trailing P/E is incalculable, and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. Dynavax' estimated growth rate for this year is 44.10%. It has a total cash position on its balance sheet of just $148.28 Million. The company announced a revenue on nine months ended September 30 of $7.90MM.


DVAX data by YCharts

This stock plunged from its May high of $5.34 to a recent low in November of $2.22. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $2.91 a share. Look for volume that's tracking in close to or above its three-month average action of 6,547,844 shares.

Horizon Pharma (NASDAQ: HZNP) is a biopharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. On Dec. 3, 2012 The company announced that its product called Rayos (prednisone) delayed release tablets are now available to U.S. physicians to treat a broad range of diseases, including rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma and chronic obstructive pulmonary disease.

Horizon Pharma has a market cap of $141.04 million. Its trailing P/E is incalculable and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. Horizon's estimated growth rate for this year is -788.84%. It has a total cash position on its balance sheet of just $121.33 Million. The company announced a revenue on nine months ended September 30 of $12.88 Million.


HZNP data by YCharts

This stock plunged from its July high of $8.72 to a recent low in November of $2.03. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $2.52 a share. Look for volume that's tracking in close to or above its three-month average action of 933,422 shares.

Somaxon Pharmaceuticals (NASDAQ: SOMX) is a specialty pharmaceutical company that engages in the licensing, development, and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology.

Somaxon has a market cap of $10.63 Million. Its trailing P/E is incalculable and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. Somaxon's estimated growth rate for this year is -10.24%. It has a total cash position on its balance sheet of just $8.5 Million. The company announced a revenue on nine months ended September 30 of $8.22 Million.


SOMX data by YCharts

This stock plunged from its January high of $6.40 to a recent low in November of $1.29. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $1.56 a share. Look for volume that's tracking in close to or above its three-month average action of 59,003 shares.

Disclosure: Jorge Aura has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.

Read More

Interview With Frederic Scheer, CEO Of Cereplast

By Jorge Aura


Cereplast Inc (NASDAQ: CERP) is engaged in the development and commercialize of compostable, renewable, ecologically substitutes for petroleum-based plastics. The company produces and markets’ bio-plastics. The company was founded in 2001. Cereplast product portfolio currently consists of two top quality range of products:

- Cereplast compostable resins are made of renewable resources and are ecologically sound substitutes for fossil fuel-based plastics, replacing nearly 100% of the petroleum-based additives used in traditional plastics.
 - Cereplast sustainable resins replace up to 90% of the petroleum content used in traditional plastics.

The company acquired a production plant in Italy in October 2011. Cereplast Inc will benefit from the new laws of sustainability of plastic bags.

I contacted Cereplast CEO, Frederic Scheer, before taking the decision to invest in this company as well as to help us gain a better understanding of the company's plans and future prospects and I have had the honor of interviewing him.

[JA] First of all, I would like to thank you for this interview. Please, tell me the start of Cereplast and its long-term objectives.

[CEO] Cereplast was incorporated in September 2001 and the scope was to create a bioplastic resin manufacturer able to offer bioplastic a substitute to traditional polyolefins but made with biobased content instead of petroleum. We have experienced significant interest from a global perspective from companies seeking to market their environmental awareness, comply with new legislative initiatives which mandate the use of bioplastics and/or reduce their carbon footprint.

[JA] On June 2012, Cereplast announced it has reached a distribution agreement with Albis Plastic GMBH. How is the commercial relationship with this company developing?

[CEO] Cereplast entered into a distribution agreement with Albis GmbH, a large European distributor. We are very pleased with our initial development work with Albis and we are excited about future prospects being generated by their team. We executed our initial shipment of material and we are hopeful to report significant developments in the weeks to come.

[JA] In August, you opened a new office in India. How are your businesses evolving in India?

[CEO] Our Indian market development efforts are the most exciting opportunity in our pipeline. India has over 1.6 billion consumers in the entire subcontinent, who are extremely receptive to alternative technology cleaning up the environment. In our office in Hyderabad, south India we have organized tens of technical tests that are supported by our local Engineer who was trained in the United States. We announced this week the first product qualified to be commercialized in the Indian market and this was done in less than 3 months, a very fast sales cycle. We are expecting more announcements to come in the next few weeks and we believe that ultimately India will become a large part of our business. India is still enjoying a 6% annual growth rate and the prospects are excellent.

[JA] Congratulations for your recent nomination for Materialica's 2012 awards. What does this nomination mean to the company?

[CEO] The Materialica nomination is just another testimony that Cereplast resins are very performing and the new trend of plastic. We believe our cutting edge technology is important to the new world of plastic. Cereplast has always created trends and we continue. For instance, Cereplast invented the concept of "hybrid" resins. Today several companies are imitating us, but clearly we have an advantage. We believe that ultimately we will change the world but clearly it is a long and rocky road and it requires perseverance and tenacity. We know that we will succeed.

[JA] A.R.M.Y. Group is a partner in South Asian markets. How many annual sales can this partner provide you?

[CEO] This is a difficult question to answer; however, the addressable market in India is very significant. I believe that in the next five years, the bioplastic resins business will grow to over $250 Million. We are one of the first companies to introduce bioplastic resins in India so I am hopeful that A.R.M.Y. will be able to exploit this competitive advantage to Cereplast.

[JA] Are you planning to release any new range of products?

[CEO] R&D is the center of our success. We are working on our new technological platform for 2013-2015. We will announce a few new offerings in our resins. We are concentrating on a fewer applications, but with resins with improved performance and offers a significant economic advantage to our end users. Our new resins will be both in our Compostables® family and our Sustainables Biopolyolefins®. We are quite excited about these resins, which could become a game changer for Cereplast.

[JA] In 2011, the company ended the year with 20MM sales. Next, a constant decrease on sales is shown in your last financial reports. What is the main reason of this decrease on sales?

[CEO] 2012 is a tough year for the world economy and is a tough year for Cereplast. As you know, over 90% of our sales were made in Europe in 2011. Unfortunately, Europe entered into a recession and several of our large clients became financially challenged, leaving us with large amounts of unpaid receivables and forcing us to dedicate a lot of time and energy to recovery. This situation forced us to restructure our selling policy and we now make sales only to companies that pay upfront or open a Letter of Credit. Implementing this policy was necessary, but eliminated several small and medium sized companies and restrained our sales. In addition, legislation in Italy that was supposed to be implemented in 2011/2012 was delayed by state authorities and the demand on compostable material decreased. The combination of all of the above explained the decrease in sales we experienced. We needed to regroup and re-center our sales on new areas of growth and this is what we have done with our Indian operations. Now clearly it takes time to build up sales cycle but we are quite optimistic on the outcome for 2013.

[JA] Cereplast Inc. shares are quoted below $1 per share. What kind of measures are you going to adopt so as to meet NASDAQ market's requirements?

[CEO] We are working with the various agencies to regain compliance and we are hopeful that the current depression in our stock value will change very shortly. The fundamentals of our Company are still very good and we just need to execute on our new direction to see our stock regain the necessary levels. We have taken a proactive attitude and we are exploring options to recapitalize the company and resolve the liquidity burden through sales in India and we intend to embark in a very active investor relations campaign to reach out to our shareholders to rebuild confidence and regain market capitalization.

[JA] Is there any multinational interested in buying Cereplast?

[CEO] At this stage we are working with several large conglomerates but primarily to design specific resins. We have not entered into any M&A activity. We are open to any opportunity but believe that it would make more sense as soon as we have regained a position of strength.

Disclosure: Jorge Aura has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.

Read More

3 Dividend Stocks That Insiders Bought Last Week

A good investment strategy can be buying shares that the insiders have just bought recently. However, a better option could be that these companies offer a dividend to its investors. The insider trading is produced by executives and directors who have the most up-to-date information on their companies' prospects. Intimately acquainted with cyclical trends, order flow, supply and production bottlenecks, costs and other key ingredients of business success, these insiders are way ahead of analysts and portfolio managers, not to mention individual investors. In the next chart, we can see the influence of the insiders in the prices of the companies and the variations in their quotes.

(click to enlarge)
(Source)

Insiders' purchases may cause an increase in the prices of shares as you have seen in the top chart. So, in this article, I will write about three dividend stocks that insiders bought last week and deserve to be considered.

National American University Holdings Inc (NAUH)

This company reported a dividend of $0.16 or the equivalent of a 3.90%. Insiders have started to snap up shares in National American University Holdings. This company engages in the ownership and operation of National American University (NAU) that provides post-secondary education services primarily for working adults and other non-traditional students in the United States.

National American University has a market cap of $101.53 million and an enterprise value of $84.20 million. Its trailing P/E is 20.89, and its forward P/E is just 8.82. National American University's estimated growth rate for this year is -50.45. It has a total cash position on its balance sheet of just $27.83 million, and its total debt is at $10.49 million.

Ronald L. Shape, CEO of National American University, has just bought 2,000 shares, or $8,200 worth of stock, at $4.2 per share.


From a technical standpoint, this stock is currently trading below both its 50-day and 200-day moving averages, which is bearish. This stock plunged from its January high of $8.8 to a recent low in May of $3.48. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $4.06 a share. Look for volume that's tracking in close to or above its three-month average action of 25,895 shares.

Valhi Inc (VHI)

Valhi Inc reported a dividend of $0.20 or the equivalent of a 1.60%. Insiders have started to snap up shares in Valhi Inc. The Company operates in the chemicals, component products, and waste management businesses. The company'’s chemicals segment produces and markets titanium dioxide pigment, a white inorganic pigment used to impart whiteness, brightness, opacity, and durability for applications, such as coatings, plastics, paper, inks, food, and cosmetics.

Valhi has a market cap of $4.07 Billion and an enterprise value of $5.49 Billion. This stock trades at a cheap valuation. Its trailing P/E is 15.78, and its forward P/E is just 23.51. Valhi's estimated growth rate for this year is 352.42%. It has a total cash position on its balance sheet of just $104 million, and its total debt is at $863.80 million.

Harold C. Simmons, Chairman of the Board, has just bought 4,000 shares, or $48,800 worth of stock, at $12.2 per share.

From a technical standpoint, this stock is currently trading below both its 50-day and 200-day moving averages, which is bearish. This stock plunged from its December, 2011 high of $21.69 to a recent low in July of $10.67. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $12.36 a share. Look for volume that's tracking in close to or above its three-month average action of 26,655 shares.

Bank of South Carolina Corporation (BKSC)

Bank of South Carolina Corporation reported a dividend of $0.44 or the equivalent of a 3.70%. Insiders have started to snap up shares in Bank of South Carolina Corporation. This bank operates as the holding company for The Bank of South Carolina that provides commercial banking products and services to individuals, and small and medium-sized businesses in South Carolina.

Bank of SC has a market cap of $52.91 million and an enterprise value of $16.42 million. Its trailing P/E is 14.87, and its forward P/E is just incalculable. Bank of South Carolina's estimated growth rate for this year is 1.98%. It has a total cash position on its balance sheet of just $36.49 million, and its total debt is at $0.

Sheryl G. Sharry, CFO of Bank of South Carolina, has just bought 2,000 shares, or $22,900 worth of stock, at $11.45 per share. 


From a technical standpoint, this stock is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock plunged from its July high of $12.50 to a recent low in October of $10.85. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $11.9 a share. Look for volume that's tracking in close to or above its three-month average action of 2,520 shares.

*Chart data sourced from finviz.com, all other data sourced from yahoo.com as well as the webs of the previously mentioned companies.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it . I have no business relationship with any company whose stock is mentioned in this article.

Read More

Spain Helps For The Purchase Of Efficient Cars

"Plan of aid for the purchase of efficient cars" is a new law that the Spanish government, headed by its president Mariano Rajoy, passed last Thursday. The plan provides incentives of 2,000 euros for the purchase of a car in exchange of leaving a car of more than twelve years. But that amount could ascend up to 8,000 euros in the case of the hybrid and electric vehicles during the months of October and November. These new aid in the current situation that is happening Spain lack logic. The biggest problem of the Spanish economy is the unemployment rate in September was about 25% of the population.
Meanwhile, remains in effect until the next November 30, "the program to aid in the purchase of these vehicles" that regulates the RD 648/2011 of May 9, and it was extended on 18 November of last year, according to the following ratio:

- 2,000 euros for vehicles with electrical autonomy of 15 and 40 kilometers.
- 4,000 euros for vehicles with electrical autonomy of between 40 and 90 kilometers
- 6,000 euros for vehicles with electrical autonomy of 90 km or more.

Remember that RD 648/2011 is an ancient law dated 9 May, 2011 which is still in effect until November 18, 2012. These are two different laws. These two laws can be applied simultaneously.
In this way, with the entry into force of the PIVE (Plan of aid for the purchase of efficient cars) this Monday, until the next November 30 the two aforementioned incentive programs to the purchase of hybrid and electric cars will coexist.

However, the registrations of new passenger cars in September have confirmed that this was the worst month of the Spanish automobile market, with a record of 35,146 units. This data, according to the manufacturers of automobile associations (Anfac) and sellers (Gamvan), a decrease of 38.6 % on the 55,572 registrations of the same month in 2011. These data demonstrate that the aid that predicts the Spanish state are directed to reactive the purchase of new vehicles.
(click to enlarge)














The data of the registrations for September are known coinciding with the entry into force of the Plan PIVE of aid for the purchase of cars, which, according to Anfac and scouting locations, will allow the Spanish State to collect three euros for every euro invested. The program is EUR 75 million of budget.


Historical Chart "Car Sales in Spain"

(click to enlarge)















In this graph can be checked as during the months of October and November sales of vehicles started a new impetus. This new law will support moderately the recovery of the sector.

Ford Motor Co. (F), General Motors Company (GM), PSA Peugeot Citroen (PEUGY.PK), Suzuki Motor Corp (SZKMF.PK), Kia Motors Corp. (KIMTF.PK), Volkswagen AG (VLKAY.PK) SAAB AB, Toyota Motor Corporation (TM), Tata Motors Limited (TTM), BMW, Renault are the most favored companies because of its strong position in Spain.

Conclusion

This new law could allow companies in the sector to recover the lost sales of the year during the months of October and November but the situation in Spain is on the edge of the economic abyss. The country will likely begin the steps to request a rescue to the European Union.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Read More

2 Stocks Upgraded On October 5 To Consider

Speculating on companies whose ratings have been recently changed by analysts can be a good short-term strategy. Normally, companies will see increases in their prices after these changes. The ratings are updated daily and can therefore change daily. They can change because of a change in the analyst's estimate of the stock's fair value, a change in the analyst's assessment of a company's business risk, or a combination of any of these factors. 

I assessed companies which were upgraded on October 5, and I chose the two companies with a change in ratings to consider.
The companies with significant changes are:

• Informatica Corporation (INFA) changed rating from neutral to buy.
• The Pep Boys—Manny, Moe & Jack (PBY) changed rating from hold to buy.

An upgrade generally tends to increase the price while a downgrade does the opposite. However, it is not only the change but the reason for the change that is important to understand. I have chosen these two companies because the analysts have commented on the reasons why they have changed the ratings which let me do a better analysis.

These two stocks are valued for the change from sell, hold, market perform or neutral to buy or strong buy. It is considered a very significant change because ratings had remained static for a long time. This change has to strongly favor the valuation of the companies mentioned above as well as the vision of future investors. Normally, these changes for the better are due to lower debt and improvement of the companies' cash. These are two keys to perform a follow-up or think in any purchase of these stocks.
Here is a look at the two stocks:

Informatica Corporation

Informatica Corporation provides enterprise data integration and data quality software and services worldwide. The company offers PowerCenter, which integrates data virtually from business systems in various formats and delivers that data throughout the enterprise; PowerExchange that enables information technology organizations to access the sources of enterprise data without having to develop custom data access programs and Data Services for finding, integrating and managing data in the enterprise.
Informatica Corporation has a market cap of $2.94 Billion and an enterprise value of $2.26 Billion. Its trailing P/E is 26.53, and its forward P/E is just 16.43. Informatica's estimated growth rate for this year is 27.17%. It has a total cash position on its balance sheet of just $565.28 Million, and its total debt is at 0. So, its total debt/equity is just 0.

New Rating

Nomura Securities upgraded Informatica from Neutral to Buy but cut its price target from $38 to $33
Analyst at Nomura Securities, Rick Sherlund, said:

"This will likely take several quarters to get through, although we like the current risk / reward in the stock. New sales management is in transition and the recovery in license revenues will likely take several quarters."

My Rating and Technical Analysis

Informatica Corporation's revenue / EPS estimates for 2012 and 2013 are now $798 / $1.28 and $865 / $1.40 versus estimates prior to the pre-announcement of $827 / $1.45 and $930 / $1.63, respectively. Nomura analysts expect improved earnings in the medium term. They base their opinion on the sales growth on the consolidation of new licenses. Although Nomura has cut its target price of Informatica Corporation, I do not find logical foundations to support its position because Informatica has cut its estimates of annual sales at 3% for 2012 and 2013. The most important risk on this stock is that the company's quarter revenues do not have the market's expected increase.

 













(click to enlarge)
From a technical standpoint, this stock is currently trading below both its 50-day and 200-day moving averages, which is bearish. This stock plunged from its April high of $54.49 to a recent low in October of $23.83. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $27.74 a share. Look for volume that's tracking in close to or above its three-month average action of 3,013,479 shares.

The Pep Boys—Manny, Moe & Jack

The Pep Boys—Manny, Moe & Jack together with its subsidiaries, provides automotive repair and maintenance services, tires, parts, and accessories. Its product lines consist of tires; batteries; new and remanufactured parts for vehicles; chemicals and maintenance items; fashion, electronic, and performance accessories; and non-automotive merchandise, such as generators, power tools, and personal transportation products.

The company has a market cap of $544.21 Million and an enterprise value of $697.67M Million. This stock trades at a cheap valuation. Its trailing P/E is 14.88, and its forward P/E is just 16.30. The Pep BoysManny's estimated growth rate for this year is 36.96%. It has a total cash position on its balance sheet of just $150.83 Million, and its total debt is at $304.25 Million. So, its total debt/equity is just 55.99.

New Rating
Benchmark upgraded Pep Boys - Manny, Moe & Jack from Hold to Buy with a price target of $12.00 (from $10.00).

Analyst at Benchmark, Ronald Bookbinder, said:

"We believe an improving tire profit environment and a possible debt refinance could provide catalysts for earnings improvement, despite weakness on discretionary items. We believe the tire profit margin environment has started to show improvement with further improvement coming in Q4. The balance sheet is strong, as the Company builds cash to pay down and refinance debt."

My Rating and Technical Analysis
Benchmark expects a growth in sales of tires in the Q4. The financial position of the company is going through hard times due to the high debt. If the company achieves a refinancing of debt, stock's prices could be higher, but the most important risk is that the company's quarter revenues do not have the market's expected increase. In my opinion, the risk/return is not attractive. I would expect a growth on sales in the next financial report.

 













(click to enlarge)
From a technical standpoint, this stock is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock plunged from its February high of $15.46 to a recent low in June of $8.31. After hitting that low, the stock bounced to its current price of $10.27. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $10.45 a share. Look for volume that's tracking in close to or above its three-month average action of 595,255shares.

*Chart data sourced from finviz.com, all other data sourced from yahoo.com.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Read More

Neomedia Technologies: Apple and Microsoft be interested?

A consortium formed by Microsoft and Apple might be interested in several patents for the company Neomedia (OTC:NEOM) suggest different people within the sector. It must be remembered that the company Neomedia technologies has more than 500 patents that could be valued according to some experts in more than $500MM. This reason could give an explanation to the strong increase in volume that leads the company in the last four days. This reason could assess the company Neomedia in more than $800MM.

About Neomedia Technologies
NeoMedia Technologies, Inc. (NeoMedia) utilizes the mobile phone by leveraging barcodes (printed symbols) as a mechanism to link brands, advertisers, carriers, retailers and consumers using the mobile Internet. With the barcode ecosystem technology, NeoMedia transforms mobile phones with cameras into barcode scanners, which provide instant access to mobile Web content whenever a barcode is scanned. NeoMedia provides the infrastructure to facilitate mobile barcode scanning and its associated commerce globally. The mobile barcode ecosystem software reads and transmits data from one-dimensional (1D) and two-dimensional (2D) barcodes to its intended destination. The code management and clearinghouse platforms create, connect, record, and transmit the transactions embedded in the barcodes. In order to provide mobile marketing solutions, NeoMedia also offers barcode scanning hardware that reads barcodes displayed on mobile phone screens.

Disclosure: I am long NEOM..


Additional disclosure: This article is intended for informational and entertainment use only and should not be construed as professional investment advice. Always do you own complete due diligence before buying and selling any stock.

Read More

3 Biotech Stocks Undervalued

Approaching the ASCO conference is a good opportunity to take positions in 3 biotechnology companies undervalued. Every year the percentage of return and growth as they approach this time is usually high.

Telik, Inc. (TELK), The price to book ratio is 0.50. The company has a drug in Phase 2 TELINTRA ® Trial in Myelodysplastic Syndrome, in Phase 2 Trial in Severe Chronic Neutropenia and Phase 1 Combination Trial with Revlimid in Myelodysplastic Syndrome. He also continues his research in Telcyta ® while in Phase 2 trial using Telcyta ® in MCL, DLBCL & MM.


Columbia Laboratories Inc. (CBRX) The price to sales ratio is 1.76. The company has Prochieve ® 8% (Reduction of Risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy and NDA filed April 2011), COL-1777 Indication: Gynecological Procedures Associated with pain in Phase II and COL -2401 for bacterial vaginosis (Pre-clinical)


BioSante Pharmaceuticals, Inc. (BPAX) The price to book ratio is 4.14. The company has in Phase III LibiGel ® Efficacy Results, Cancer Vaccines: Chronic Myeloid Leukemia CML in Phase II clinical trial, Acute Myeloid Leukemia (AML) in Phase II and Phase II Pancreatic Cancer in, The Pill-Plus ™ is an oral Currently in Development contraceptive in Phase II.


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Read More